All News Iterum Therapeutics plc

Equities

ITRM

IE000TTOOBX0

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
1.58 ^USD	0.00%		+8.22%	-19.80%

Mar. 28	Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024
Mar. 28	Iterum Therapeutics plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024	Mar. 28
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 28	AQ
Iterum Therapeutics plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 28	CI
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024	Mar. 21	AQ
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat	Mar. 15	AQ
Iterum Therapeutics Provides Business Update	Mar. 06	AQ
Iterum Therapeutics Plans to Engage Financial Advisor to Evaluate Strategic Alternatives	Mar. 05	CI
HC Wainwright Upgrades Iterum Therapeutics to Buy From Neutral, Price Target is $6	Feb. 07	MT
Transcript : Iterum Therapeutics plc - Special Call	Jan. 30
Iterum Therapeutics Says UTI Drug Trial Met Primary Endpoint	Jan. 30	DJ
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	Jan. 30	PR
Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract Infections	Jan. 30	CI
Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023	Dec. 29	CI
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule	Dec. 04	AQ
Transcript : Iterum Therapeutics plc, Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Iterum Therapeutics Reports Third Quarter 2023 Financial Results	Nov. 14	AQ
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023	Nov. 07	AQ
Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	23-10-24	AQ
Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	23-10-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Iterum Therapeutics plc

Equities

ITRM

IE000TTOOBX0

All News

Filters